ArticleEuropean journal of nuclear medicine and molecular imaging2022
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04560725 (PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Ablation-induced collagen exposure enables dual-modal nuclear imaging-guided local radionuclide therapy.Journal of nanobiotechnology · 2026Article
- Preclinical evaluation and first-in-human study ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Development of a novelJournal for immunotherapy of cancer · 2025Article
- Enhancing the Half-Life of ODAP-Urea Based Radioligands by Incorporating Albumin-Binding Moieties.Molecular imaging and biology · 2025Article
- Design, preclinical evaluation, and first-in-human PET study of [European journal of nuclear medicine and molecular imaging · 2025Article
- Recent advancements in new tracers from first-in-human studies.Annals of nuclear medicine · 2024Review
- Molecular Eye: A System for Precise Diagnosis and Treatment of Major Clinical Diseases Based on Molecular Probe Technology.Chemical & biomedical imaging · 2024Review
- "One Method to Label Them All": A Single Fully Automated Protocol for GMP-CompliantCurrent radiopharmaceuticals · 2024Article
- Case report: Systemic tuberculosis with prostate involvement mimicking prostate cancer with multiple metastases onFrontiers in medicine · 2024Article
- Radiometallation and photo-triggered release of ready-to-inject radiopharmaceuticals from the solid phase.Chemical science · 2023Article
- Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling.RSC medicinal chemistry · 2023Review
- Ultrasmall, elementary and highly translational nanoparticle X-ray contrast media from amphiphilic iodinated statistical copolymers.Acta pharmaceutica Sinica. B · 2023Article
- Article
- State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956-2022).European journal of nuclear medicine and molecular imaging · 2022Article
- Preclinical evaluation and first in human study of AlFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate-specific membrane antigen (PSMA) is a promising target for prostate cancer imaging and therapy. The most commonly used scaffold incorporates a glutamate-urea (Glu-Urea) function. We recently developed oxalyldiaminopropionic acid-urea (ODAP-Urea) PSMA ligands in an attempt to improve upon the pharmacokinetic properties of existing agents. Here, we report the synthesis of an optimized
methodsTwelve ODAP-Urea-based ligands were synthesized and radiolabeled with
resultsLigands were synthesized in 11.1-44.4% yield and > 95% purity. They have high affinity to PSMA (K
conclusionThe optimized ODAP-Urea-based ligand [
trial registrationClinicalTrials.gov Identifier: NCT04560725, Registered 23 September 2020. https://clinicaltrials.gov/ct2/show/NCT04560725.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.